Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Joerg Herrmann MD
Joerg Herrmann MD Associate Editor
James Udelson MD
James E. Udelson MD Advisory Board
J. William McEvoy MB BCh BAO, MEd, MHS, PhD, FRCPI
J. William McEvoy MB BCh BAO, MEd, MHS, PhD, FRCPI Advisory Board
See All Experts
featured
Published in Cardiology and
2 other channels

Journal Scan / Research · January 04, 2017

Fenofibrate Therapy Reduces Long-Term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes

JAMA Cardiology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Marja-Riitta Taskinen MD

JAMA Cardiology
Association of Fenofibrate Therapy With Long-Term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
JAMA Cardiol 2016 Dec 28;[EPub Ahead of Print], MB Elam, HN Ginsberg, LC Lovato, M Corson, J Largay, LA Leiter, C Lopez, PJ O'Connor, ME Sweeney, D Weiss, WT Friedewald, JB Buse, HC Gerstein, J Probstfield, R Grimm, F Ismail-Beigi, DC Goff, JL Fleg, Y Rosenberg, RP Byington

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated